Filter
Reset all

Subjects

Content Types

Countries

AID systems

API

Data access

Data access restrictions

Database access

Database licenses

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

Metadata standards

PID systems

Provider types

Quality management

Repository languages

Software

Syndications

Repository types

Versioning

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 5 result(s)

The Neuro C-BIG Repository Data Portal (Beta)

C-BIG Repository Data Portal - Beta Version

Subject(s)
Content type(s)
Country
An Open Science resource that promotes scientific research and discovery in neurological diseases and accelerates the development of new treatments. It includes a growing collection of biospecimens, longitudinal clinical and neuropsychiatric information, imaging and genetic data from patients with neurological disease as well as healthy controls.

EyeGENE

The National Ophthalmic Genotyping and Phenotyping Network

Subject(s)
Content type(s)
Country
The eyeGENE® Research Resource is open for approved research studies. Application details here Researchers and clinicians are actively developing gene-based therapies to treat ophthalmic genetic diseases that were once considered untreatable.

Neuroscience Information Framework

NIF

Subject(s)
Content type(s)
Country
The Neuroscience Information Framework is a dynamic index of data, materials, and tools. Please note, we do not accept direct data deposits, but if you wish to make your data repository or database available through our search, please contact us. An initiative of the NIH Blueprint for Neuroscience Research, NIF advances neuroscience research by enabling discovery and access to public research data and tools worldwide through an open source, networked environment.

OASIS

Open Access Series of Imaging Studies

Subject(s)
Content type(s)
Country
OASIS-3 is the latest release in the Open Access Series of Imaging Studies (OASIS) that aimed at making neuroimaging datasets freely available to the scientific community. By compiling and freely distributing this multi-modal dataset, we hope to facilitate future discoveries in basic and clinical neuroscience. Previously released data for OASIS-Cross-sectional (Marcus et al, 2007) and OASIS-Longitudinal (Marcus et al, 2010) have been utilized for hypothesis driven data analyses, development of neuroanatomical atlases, and development of segmentation algorithms. OASIS-3 is a longitudinal neuroimaging, clinical, cognitive, and biomarker dataset for normal aging and Alzheimer’s Disease. The OASIS datasets hosted by central.xnat.org provide the community with open access to a significant database of neuroimaging and processed imaging data across a broad demographic, cognitive, and genetic spectrum an easily accessible platform for use in neuroimaging, clinical, and cognitive research on normal aging and cognitive decline. All data is available via www.oasis-brains.org.

PRO-ACT

Pooled Resource Open-Access ALS Clinical Trials Database

Subject(s)
Content type(s)
Country
The PRO-ACT platform houses the largest ALS clinical trials dataset ever created. It is a powerful tool for biomedical researchers, statisticians, clinicians, or anyone else interested in "Big Data." PRO-ACT merges data from existing public and private clinical trials, generating an invaluable resource for the design of future ALS clinical trials. The database will also contribute to the identification of unique observations, novel correlations, and patterns of ALS disease progression, as well as a variety of still unconsidered analyses. More than 600,000 people around them world are battling ALS. The disease strikes indiscriminately, and typically patients will die within 2-5 years following diagnosis. Currently, there are no effective treatments or a cure for ALS. Users of PRO-ACT are helping to accelerate the discovery, development, and delivery of ALS treatments, which will provide hope to patients and their families.